Discovery and hit-to-lead evaluation of piperazine amides as selective, state-dependent NaV1.7 inhibitors

NaV1.7 is a particularly compelling target for the treatment of pain. Herein, we report the discovery and evaluation of a series of piperazine amides that exhibit state-dependent inhibition of NaV1.7. After demonstrating significant pharmacodynamic activity with early lead compound 14 in a NaV1.7-de...

Full description

Saved in:
Bibliographic Details
Published inMedChemComm Vol. 8; no. 4; pp. 744 - 754
Main Authors Sparling, Brian A, Yi, S, Able, J, Bregman, H, DiMauro, Erin F, Foti, R S, Gao, H, Guzman-Perez, A, Huang, H, Jarosh, M, Kornecook, T, Ligutti, J, Milgram, B C, Moyer, B D, Youngblood, B, Yu, V L, Weiss, M M
Format Journal Article
LanguageEnglish
Published 01.04.2017
Online AccessGet full text

Cover

More Information
Summary:NaV1.7 is a particularly compelling target for the treatment of pain. Herein, we report the discovery and evaluation of a series of piperazine amides that exhibit state-dependent inhibition of NaV1.7. After demonstrating significant pharmacodynamic activity with early lead compound 14 in a NaV1.7-dependent behavioural mouse model, we systematically established SAR trends throughout each sector of the scaffold. The information gleaned from this modular analysis was then applied additively to quickly access analogues that encompass an optimal balance of properties, including NaV1.7 potency, selectivity over NaV1.5, aqueous solubility, and microsomal stability.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2040-2503
2040-2511
DOI:10.1039/c6md00578k